Quick Answer
Celldex Therapeutics, Inc. reported Total Assets of $582.98 million for the year ending 2025.
- Celldex Therapeutics, Inc. showed a decrease of -26.4% in Total Assets from 2024 to 2025.
- This data is from Celldex Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $118.48 million | Q3 2011: $108.45 million | Q1 2012: $136.74 million | Q2 2012: $122.13 million | Q3 2012: $119.84 million | Q1 2013: $224.37 million | Q2 2013: $196.23 million | Q3 2013: $180.96 million | Q1 2014: $318.70 million | Q2 2014: $297.59 million | Q3 2014: $271.67 million | Q1 2015: $407.70 million | Q2 2015: $383.22 million | Q3 2015: $352.63 million | Q1 2016: $301.93 million | Q2 2016: $271.21 million | Q3 2016: $251.95 million | Q1 2017: $360.05 million | Q2 2017: $346.07 million | Q3 2017: $319.42 million | Q1 2018: $191.38 million | Q2 2018: $178.38 million | Q3 2018: $168.29 million | Q1 2019: $147.58 million | Q2 2019: $142.24 million | Q3 2019: $131.84 million | Q1 2020: $112.50 million | Q2 2020: $261.40 million | Q3 2020: $255.77 million | Q1 2021: $219.07 million | Q2 2021: $204.55 million | Q3 2021: $460.20 million | Q1 2022: $424.04 million | Q2 2022: $402.96 million | Q3 2022: $369.23 million | Q1 2023: $324.52 million | Q2 2023: $299.31 million | Q3 2023: $280.26 million | Q1 2024: $868.85 million | Q2 2024: $845.59 million | Q3 2024: $823.18 million | Q1 2025: $739.47 million | Q2 2025: $692.41 million | Q3 2025: $648.44 million.
- Over the full 16 years of available data (2010 to 2025), Celldex Therapeutics, Inc.'s Total Assets has grown by 430.3%.
- Historical annual values: Fiscal year 2025: $582.98 million | Fiscal year 2024: $792.34 million | Fiscal year 2023: $465.63 million | Fiscal year 2022: $352.74 million | Fiscal year 2021: $444.65 million | Fiscal year 2020: $235.84 million | Fiscal year 2019: $122.93 million | Fiscal year 2018: $155.81 million | Fiscal year 2017: $315.62 million | Fiscal year 2016: $383.36 million | Fiscal year 2015: $337.58 million | Fiscal year 2014: $248.01 million | Fiscal year 2013: $347.10 million | Fiscal year 2012: $125.54 million | Fiscal year 2011: $97.99 million | Fiscal year 2010: $109.94 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: